The impact of diabetes mellitus and metformin treatment on survival of patients with advanced pancreatic cancer undergoing chemotherapy

Cancer Research and Treatment

Volumn 48, Issue 1, 2016, Pages 171-179

  Choi, Younak ^a   Kim, Tae Yong ^a,b   Oh, Do Youn ^a,b   Lee, Kyung Hun ^a,b   Han, Sae Won ^a,b   Im, Seock Ah ^a,b   Kim, Tae You ^a,b   Bang, Yung Jue ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Antineoplastic agents; Diabetes mellitus; Metformin; Pancreatic neoplasms; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GEMCITABINE; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PANCREAS CANCER; RETROSPECTIVE STUDY; COMPLICATION; DIABETIC COMPLICATION; MORTALITY; PANCREAS TUMOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84957578772     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2014.292     Document Type: Article

References (25)

1. Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS, et al. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2010;28:5327-47.
2. Andre T, Balosso J, Louvet C, Gligorov J, Callard P, de Gramont A, et al. Adenocarcinoma of the pancreas. General characteristics. Presse Med. 1998;27:533-6.
3. Chiu CC, Huang CC, Chen YC, Chen TJ, Liang Y, Lin SJ, et al. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan. Intern Med. 2013;52:939-46.
4. Kuuselo R, Savinainen K, Azorsa DO, Basu GD, Karhu R, Tuzmen S, et al. Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res. 2007; 67:1943-9.
5. Asano T, Yao Y, Shin S, McCubrey J, Abbruzzese JL, Reddy SA. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res. 2005;65:9164-8.
6. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancerassociated diabetes mellitus. Gastroenterology. 2008;134:981-7.
7. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076-83.
8. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88-95.
9. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95-101.
10. Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CW Jr. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control. 1998;9:403-10.
11. Wakasugi H, Funakoshi A, Iguchi H. Clinical observations of pancreatic diabetes caused by pancreatic carcinoma, and survival period. Int J Clin Oncol. 2001;6:50-4.
12. Chu CK, Mazo AE, Goodman M, Egnatashvili V, Sarmiento JM, Staley CA, et al. Preoperative diabetes mellitus and longterm survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17:502-13.
13. Mizuno S, Nakai Y, Isayama H, Takahara N, Miyabayashi K, Yamamoto K, et al. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Pancreatology. 2013;13:285-9.
14. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137:482-8.
15. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012;18: 2905-12.
16. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011;364: 719-29.
17. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269-73.
18. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab. 2013;24:469-80.
19. Hwang AL, Haynes K, Hwang WT, Yang YX. Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas. 2013;42:1054-9.
20. Lee CK, Jung M, Jung I, Heo SJ, Jeong YH, An JY, et al. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. Ann Surg. 2015 Jan 8 [Epub]. http://dx.doi.org/10.1097/SLA.0000000000001086.
21. Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer. 2012;19:F9-F26.
22. Hwang A, Narayan V, Yang YX. Type 2 diabetes mellitus and survival in pancreatic adenocarcinoma: a retrospective cohort study. Cancer. 2013;119:404-10.
23. Yuan C, Rubinson DA, Qian ZR, Wu C, Kraft P, Bao Y, et al. Survival among patients with pancreatic cancer and longstanding or recent-onset diabetes mellitus. J Clin Oncol. 2015; 33:29-35.
24. Nakai Y, Isayama H, Sasaki T, Mizuno S, Sasahira N, Kogure H, et al. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Pancreas. 2013;42:202-8.
25. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013;10:423-33.